search

1-5 of 5

Save search

Sort by

Sort Order Select

Journal Article

Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018–19)

PDF

Helio S Sader and others

Journal of Antimicrobial Chemotherapy, Volume 77, Issue 10, October 2022, Pages 2642–2649, https://doi.org/10.1093/jac/dkac233

Published: 28 July 2022

Supplementary data

Journal Article

Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012–18

PDF

Helio S Sader and others

Journal of Antimicrobial Chemotherapy, Volume 75, Issue 10, October 2020, Pages 2907–2913, https://doi.org/10.1093/jac/dkaa278

Published: 10 July 2020

Journal Article

Antimicrobial activity of POL7306 tested against clinical isolates of Gram-negative bacteria collected worldwide

PDF

Helio S Sader and others

Journal of Antimicrobial Chemotherapy, Volume 75, Issue 6, June 2020, Pages 1518–1524, https://doi.org/10.1093/jac/dkaa020

Published: 22 February 2020

Journal Article

Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015–16

PDF

Michael A Pfaller and others

Journal of Antimicrobial Chemotherapy, Volume 73, Issue 10, October 2018, Pages 2748–2756, https://doi.org/10.1093/jac/dky235

Published: 29 June 2018

Journal Article

EDITOR'S CHOICE

Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012–15)

PDF

Michael A. Pfaller and others

Journal of Antimicrobial Chemotherapy, Volume 72, Issue 5, May 2017, Pages 1386–1395, https://doi.org/10.1093/jac/dkx009

Published: 06 February 2017

Modify your search

Availability

NARROW

Format

Type

Section

Category

Publication date

Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018–19)

Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012–18

Antimicrobial activity of POL7306 tested against clinical isolates of Gram-negative bacteria collected worldwide

Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015–16

Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012–15)

Email alerts

Modify your search

Publication date

Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018–19) Free

Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012–18 Free

Antimicrobial activity of POL7306 tested against clinical isolates of Gram-negative bacteria collected worldwide Free

Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015–16 Free

Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012–15) Free

Email alerts

This Feature Is Available To Subscribers Only

Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018–19)

Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012–18

Antimicrobial activity of POL7306 tested against clinical isolates of Gram-negative bacteria collected worldwide

Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015–16

Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012–15)